On May 19, 2026 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, reported that Dr. Bing Hou has been appointed Chief Scientific Officer, reporting directly to Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Hou’s appointment underscores Antengene’s commitment to strengthening its innovation-driven R&D model as a global biotech company. In this role, Dr. Hou will lead Antengene’s efforts across Drug Discovery, Translational Medicine, and Chemistry, Manufacturing and Controls (CMC), with a focus on deepening the Company’s research engine and building a pipeline of next-generation therapeutic candidates with transformational potential.
Since joining Antengene in 2019, Dr. Hou has been a key member of the Company’s scientific leadership team, and prior to this appointment, served as Vice President, Head of Discovery Science & Translational Medicine. During his tenure, he has built and led a high-caliber discovery organization, helped guide Antengene’s R&D initiatives, advanced internally discovered programs into clinical development, and played an important role in establishing newly developed proprietary platforms designed to support future innovation programs.
"We are very pleased to appoint Dr. Bing Hou as Chief Scientific Officer of Antengene," said Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene. "Dr. Hou has made significant contributions to shaping Antengene’s scientific strategy and strengthening our internal research capabilities. Under his leadership, Antengene has built and advanced AnTenGager, the Company’s proprietary T-cell engager (TCE) 2.0 platform with broad applicability across autoimmune diseases, solid tumors and hematological malignancies, as well as other novel programs and platform technologies that support our next-generation pipeline. The global license agreement Antengene entered into with UCB for ATG-201, a CD19 x CD3 TCE developed from the AnTenGager platform for B cell-related autoimmune diseases, further highlights the strategic value of Antengene’s proprietary discovery capabilities. As we enter our next stage of growth, we look forward to Dr. Hou’s continued leadership in expanding our innovative pipeline, and bringing forward transformative therapies for patients globally."
"I am honored and excited to step into the role of Chief Scientific Officer at Antengene," said Dr. Bing Hou, Chief Scientific Officer of Antengene. "Antengene is advancing a number of highly promising programs across oncology and autoimmune diseases, and I believe we are well positioned to build a next-generation pipeline grounded in rigorous biology, differentiated mechanisms and platform innovation. Looking ahead, we will continue to focus on programs with the potential to address significant unmet medical needs, including T cell engagers developed from our proprietary AnTenGager platform; ATG-125, a B7-H3 x PD-L1 bispecific antibody-drug conjugate (ADC) designed to combine ADC and immuno-oncology mechanisms; and ATG-207, a globally first-in-class αCD3-TGF-β bifunctional fusion protein for T cell-driven autoimmune diseases. I look forward to continuing to work closely with the Antengene team to translate our differentiated science and platform capabilities into a robust pipeline of innovative medicines."
Dr. Hou received his Ph.D. in Biomedicine from the University of Leeds in the United Kingdom. He has published multiple high-impact research papers as first author or corresponding author in leading journals including Nature, Science Advances, and Cancer Research. He has filed more than 40 patent applications for novel therapeutics. As an inventor and/or principal leader, he has advanced multiple first-in-class or best-in-class drug candidates into various stages of clinical development.
(Press release, Antengene, MAY 19, 2026, View Source [SID1234665878])